Gainers
- Rapport Therapeutics (NASDAQ:RAPP) stock increased by 138.2% to $34.21 during Monday's pre-market session. The market value of their outstanding shares is at $524.1 million.
- Dianthus Therapeutics (NASDAQ:DNTH) shares rose 66.94% to $44.24. The market value of their outstanding shares is at $852.9 million.
- Biodexa Pharmaceuticals (NASDAQ:BDRX) stock moved upwards by 30.97% to $7.4. The company's market cap stands at $3.5 million.
- Beyond Air (NASDAQ:XAIR) stock rose 27.6% to $2.82. The market value of their outstanding shares is at $11.5 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCCP) stock rose 25.0% to $6.0.
- Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 23.96% to $24.0. The market value of their outstanding shares is at $169.4 million.
Losers
- MEI Pharma (NASDAQ:MEIP) stock declined by 24.8% to $3.18 during Monday's pre-market session. The market value of their outstanding shares is at $138.9 million.
- CDT Equity (NASDAQ:CDT) stock fell 21.78% to $0.92. The market value of their outstanding shares is at $3.5 million.
- Summit Therapeutics (NASDAQ:SMMT) stock decreased by 20.48% to $20.66. The market value of their outstanding shares is at $19.2 billion.
- iSpecimen (NASDAQ:ISPC) stock declined by 17.65% to $0.7. The company's market cap stands at $7.0 million.
- Indaptus Therapeutics (NASDAQ:INDP) stock declined by 16.75% to $2.75. The market value of their outstanding shares is at $3.6 million.
- Gelteq (NASDAQ:GELS) shares fell 14.75% to $1.33. The company's market cap stands at $15.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
CDTCDT Equity Inc
$0.4323-33.4%
DNTHDianthus Therapeutics Inc
$33.79-2.76%
GELSGelteq Ltd
$1.35-0.77%
INDPIndaptus Therapeutics Inc
$3.83-11.1%
ISPCiSpecimen Inc
$0.8500-6.34%
MCRBSeres Therapeutics Inc
$18.74-3.90%
RAPPRapport Therapeutics Inc
$26.50-0.90%
SMMTSummit Therapeutics Inc
$20.80-8.17%
XAIRBeyond Air Inc
$2.43-9.67%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.